Radiomic Features Are Associated With EGFR Mutation Status in Lung Adenocarcinomas

Halpenny, 2014, Are there imaging characteristics associated with lung adenocarcinomas harboring ALK rearrangements?, Lung Cancer, 86, 190, 10.1016/j.lungcan.2014.09.007

Ganeshan, 2012, Tumour heterogeneity in non–small-cell lung carcinoma assessed by CT texture analysis: a potential marker of survival, Eur Radiol, 22, 796, 10.1007/s00330-011-2319-8

Mok, 2009, Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma, N Engl J Med, 361, 947, 10.1056/NEJMoa0810699

Jackman, 2009, Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non–small-cell lung cancer patients: results of an online tumor registry of clinical trials, Clin Cancer Res, 15, 5267, 10.1158/1078-0432.CCR-09-0888

Riely, 2006, Clinical course of patients with non–small-cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib, Clin Cancer Res, 12, 839, 10.1158/1078-0432.CCR-05-1846

Yang, 2012, LUX-Lung 3: a randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations, ASCO Annual Meeting, 10.1200/jco.2012.30.18_suppl.lba7500

Maemondo, 2010, Gefitinib or chemotherapy for non–small-cell lung cancer with mutated EGFR, N Engl J Med, 362, 2380, 10.1056/NEJMoa0909530

Kobayashi, 2009, First-line gefitinib versus first-line chemotherapy by carboplatin (CBDCA) plus paclitaxel (TXL) in non–small-cell lung cancer (NSCLC) patients (pts) with EGFR mutations: a phase III study (002) by North East Japan Gefitinib Study Group, ASCO Annual Meeting

Mitsudomi, 2010, Gefitinib versus cisplatin plus docetaxel in patients with non–small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial, Lancet Oncol, 11, 121, 10.1016/S1470-2045(09)70364-X

Paez, 2004, EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy, Science, 304, 1497, 10.1126/science.1099314

Kosaka, 2004, Mutations of the epidermal growth factor receptor gene in lung cancer biological and clinical implications, Cancer Res, 64, 8919, 10.1158/0008-5472.CAN-04-2818

Shahi, 2015, Detection of EGFR-TK domain-activating mutations in NSCLC with generic PCR-based methods, Appl Immunohistochem Mol Morphol, 23, 163, 10.1097/PDM.0000000000000035

Tomonaga, 2013, Analysis of intratumor heterogeneity of EGFR mutations in mixed type lung adenocarcinoma, Clin Lung Cancer, 14, 521, 10.1016/j.cllc.2013.04.005

Bai, 2013, Detection and clinical significance of intratumoral EGFR mutational heterogeneity in Chinese patients with advanced non–small-cell lung cancer, PLoS One, 8, e54170, 10.1371/journal.pone.0054170

Taniguchi, 2008, Intratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinib, Cancer Sci, 99, 929, 10.1111/j.1349-7006.2008.00782.x

Querings, 2011, Benchmarking of mutation diagnostics in clinical lung cancer specimens, PLoS One, 6, e19601, 10.1371/journal.pone.0019601

Rizzo, 2016, CT radiogenomic characterization of EGFR, K-RAS, and ALK mutations in non–small -cell lung cancer, Eur Radiol, 26, 32, 10.1007/s00330-015-3814-0

Zhou, 2015, Comparative analysis of clinicoradiologic characteristics of lung adenocarcinomas with ALK rearrangements or EGFR mutations, Eur Radiol, 25, 1257, 10.1007/s00330-014-3516-z

Lee, 2013, Imaging characteristics of stage I non–small-cell lung cancer on CT and FDG-PET: relationship with epidermal growth factor receptor protein expression status and survival, Korean J Radiol, 14, 375, 10.3348/kjr.2013.14.2.375

Lee, 2013, Epidermal growth factor receptor mutation in lung adenocarcinomas: relationship with CT characteristics and histologic subtypes, Radiology, 268, 254, 10.1148/radiol.13112553

Kumar, 2012, Radiomics: the process and the challenges, Magn Reson Imaging, 30, 1234, 10.1016/j.mri.2012.06.010

Parmar, 2014, Robust radiomics feature quantification using semiautomatic volumetric segmentation, PLoS One, 9, e102107, 10.1371/journal.pone.0102107

Mattonen, 2014, Early prediction of tumor recurrence based on CT texture changes after stereotactic ablative radiotherapy (SABR) for lung cancer, Med Phys, 41, 033502, 10.1118/1.4866219

Weiss, 2014, Noninvasive image texture analysis differentiates K-ras mutation from pan-wildtype NSCLC and is prognostic, PLoS One, 9, e100244, 10.1371/journal.pone.0100244

Ravanelli, 2013, Texture analysis of advanced non–small-cell lung cancer (NSCLC) on contrast-enhanced computed tomography: prediction of the response to the first-line chemotherapy, Eur Radiol, 23, 3450, 10.1007/s00330-013-2965-0

Coroller, 2015, CT-based radiomic signature predicts distant metastasis in lung adenocarcinoma, Radiother Oncol, 114, 345, 10.1016/j.radonc.2015.02.015

Edge, 2010, The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM, Ann Surg Oncol, 17, 1471, 10.1245/s10434-010-0985-4

Travis, 2011, International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society: international multidisciplinary classification of lung adenocarcinoma: executive summary, Proc Am Thorac Soc, 8, 381, 10.1513/pats.201107-042ST

Locatelli-Sanchez, 2013, Routine EGFR molecular analysis in non–small-cell lung cancer patients is feasible: exons 18–21 sequencing results of 753 patients and subsequent clinical outcomes, Lung, 191, 491, 10.1007/s00408-013-9482-4

Balagurunathan, 2014, Test-retest reproducibility analysis of lung CT image features, J Digit Imaging, 27, 805, 10.1007/s10278-014-9716-x

Gu, 2013, Automated delineation of lung tumors from CT images using a single-click ensemble segmentation approach, Pattern Recognit, 46, 692, 10.1016/j.patcog.2012.10.005

Velazquez, 2012, A semiautomatic CT-based ensemble segmentation of lung tumors: Comparison with oncologists' delineations and with the surgical specimen, Radiother Oncol, 105, 167, 10.1016/j.radonc.2012.09.023

Balagurunathan, 2014, Reproducibility and prognosis of quantitative features extracted from CT images, Transl Oncol, 7, 72, 10.1593/tlo.13844

Randen, 1999, Filtering for texture classification: a comparative study, IEEE Trans Pattern Anal Mach Intell, 21, 291, 10.1109/34.761261

da Cunha Santos, 2011, EGFR mutations and lung cancer, Annu Rev Pathol, 6, 49, 10.1146/annurev-pathol-011110-130206

Liu, 2014, Prognostic value of epidermal growth factor receptor mutations in resected lung adenocarcinomas, Med Oncol, 31, 771, 10.1007/s12032-013-0771-9

Ozkan, 2015, CT gray-level texture analysis as a quantitative imaging biomarker of epidermal growth factor receptor mutation status in adenocarcinoma of the lung, AJR Am J Roentgenol, 205, 1016, 10.2214/AJR.14.14147

Zhao, 2009, Evaluating variability in tumor measurements from same-day repeat CT scans of patients with non–small-cell lung cancer, Radiology, 252, 263, 10.1148/radiol.2522081593

Hsu, 2014, Correlation between EGFR mutation status and computed tomography features in patients with advanced pulmonary adenocarcinoma, J Thorac Imaging, 29, 357, 10.1097/RTI.0000000000000116